TORONTO, June 15, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that epratuzumab labeled with the potent radioisotope, yttrium-90 (Y-90), when given in small fractionated doses to patients with non-Hodgkin's lymphoma (NHL), achieved high rates of durable responses at total Y-90 doses exceeding the 32-mCi limit approved for a single dose of ibritumomab tiuxetan. Results from this multicenter, open label study were presented at the Society of Nuclear Medicine 56th Annual Meeting.
